ImmunityBio Pipeline

DISEASE
TRIANGLE OFFENSE
TRIAL SITES/COLLABORATORS
PHASE

* Investigator-sponsored studies

Anktiva® (N-803) is an interleukin-15 superagonist fusion protein that is designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells and (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Both agents are in late-stage clinical development by ImmunityBio, which has exclusive, worldwide rights to the agents. Pembrolizumab, sold under the brand KEYTRUDA®, is an FDA-approved immune checkpoint inhibitor marketed by Merck.
QUILT stands for QUantum Integrative Lifelong Trial.

How Can ImmunityBio Help You?

Solutions for Patients

Many cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

The broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

Disease
Bladder Cancer
QUILT-3.032
BCG Unresponsive NMIBC Carcinoma In-Situ & Papillary
Triangle Offense
Anktiva + BCG
Trial Sites/Collaborators
32 study locations (see clinicaltrials.gov for details)
Phase
Phase 2 / 3
Disease
Bladder Cancer
QUILT-2.005
BCG Naïve NMIBC
Triangle Offense
Anktiva + BCG
Trial Sites/Collaborators
24 study locations (see clinicaltrials.gov for details)
Phase
Phase 3
Disease
Lung Cancer
QUILT-2.023
1L Squamous & Non-Squamous Non-Small Cell – Lung Cancer Checkpoint Alone
Triangle Offense
Anktiva + Keytruda (Pembrolizumab)
Trial Sites/Collaborators
31 study locations (see clinicaltrials.gov for details)
Phase
Phase 3
Disease
Pancreatic Cancer
QUILT-88
3L Metastatic Pancreatic Cancer (Cohort B)
Triangle Offense
Aldox + Anktiva + PD-L1 t-haNK
Trial Sites/Collaborators
Hoag Memorial Presbyterian Hospital (Newport Beach, CA); Avera Cancer Institute (Sioux Falls, SD); Astera Cancer Care (East Brunswick, NJ)
Phase
Phase 2
Disease
Lynch Syndrome
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome*
Triangle Offense
Anktiva + Tri-Ad5 vaccines
Trial Sites/Collaborators
National Cancer Institute (see clinicaltrials.gov for details)
Phase
Phase 2
Disease
Glioblastoma
Planned Phase I/II randomized trial
Triangle Offense
Anktiva + bevacizumab + PD-L1 t-haNK
Trial Sites/Collaborators
Details to be announced
Phase
Phase 1
Disease
HPV
QUILT 3.100
Planned Phase I/II Human Papilloma Virus (HPV) – Lower GU, Cervical, Head & Neck
Triangle Offense
Anktiva + IBRX-042 vaccination
Trial Sites/Collaborators
Details to be announced
Phase
Phase 1
Disease
Advanced Solid Tumors
QUILT 3.076
Locally Advanced or Metastatic Solid Tumors
Triangle Offense
Anktiva + M-ceNK
Trial Sites/Collaborators
Chan Soon-Shiong Institute for Medicine (El Segundo, CA)
Phase
Phase 1
Disease
Non-Hodgkin Lymphoma
QUILT 3.092
Relapses/Refractory Non-Hodgkin Lymphoma
Triangle Offense
Anktiva + CD19 t-haNK
Trial Sites/Collaborators
Hoag Memorial Presbyterian Hospital (Newport Beach, CA)
Phase
Phase 1
Disease
SARS-CoV-2
THEMBA II T Cell Vaccine: AAHI-SC2 (Spike), AAHI-SC3 (Nucleocapsid) saRNA COVID-19 Vaccine*
Triangle Offense
Anktiva
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 1
Disease
HIV
AIDS Clinical Trials Group (ACTG) / National Institute of Allergy and Infectious Diseases (NIAID): HIV Cure Study*
Triangle Offense
Anktiva
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 1
Disease
HIV
Thailand Trial: N-803 in Acute HIV Infection*
Triangle Offense
Anktiva
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 2
Disease
HIV
NIAID / University of Minnesota: Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease*
Triangle Offense
Anktiva
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 1
Older Posts
Newer Posts
Sort by:
or